TVAX cancer vaccine - TVAX Biomedical

Drug Profile

TVAX cancer vaccine - TVAX Biomedical

Alternative Names: TVI-Brain-1; TVI-Breast-1; TVI-Colon-1; TVI-Kidney-1; TVI-Leukemia-1; TVI-Lung-1; TVI-Melanoma-1; TVI-Ovary-1; TVI-Pancreas-1; TVI-Prostate-1

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TVAX Biomedical
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - CNS cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Brain cancer; Glioma; Renal cell carcinoma
  • Phase I/II Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Prostate cancer

Most Recent Events

  • 10 Oct 2016 TVAX cancer vaccine is still in phase II and phase I/II trials for various cancer indications in the US (TVAX Biomedical pipeline, October 2016)
  • 10 Oct 2016 Phase-II clinical trials in Brain cancer in USA (IV) before October 2016 (TVAX Biomedical pipeline, October 2016)
  • 19 Aug 2015 No recent reports on development identified - Phase-I/II for Breast cancer, Colorectal cancer, Leukaemia, Lung cancer, Malignant melanoma, Ovarian cancer, Pancreatic cancer, Prostate cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top